Methods: In a randomized, double blind crossover-within-subject clinical trial, the investigators will study 18 weight- matched obese and overweight participants with known T2D, diagnosed < 20 years, and HbA1c 7.0 to 10 %, BMI: 26-32 kg/m2 treated with diet alone or diet plus metformin, and sodium/glucose cotransporter 2 (SGLT2) inhibitors (gliflozins).